Efficacy and Safety of a New Botulinum Toxin (HU-014) Versus Existing Onabotulinumtoxin A in Subjects With Moderate to Severe Glabellar Lines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Kwang Ho | - |
dc.contributor.author | Lee, Yang Won | - |
dc.contributor.author | Lee, Ji Su | - |
dc.contributor.author | Kwon, Soon Hyo | - |
dc.contributor.author | Huh, Chang Hun | - |
dc.contributor.author | Kim, Beom Joon | - |
dc.date.accessioned | 2021-07-27T04:53:24Z | - |
dc.date.available | 2021-07-27T04:53:24Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 1076-0512 | - |
dc.identifier.issn | 1524-4725 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/47900 | - |
dc.description.abstract | BACKGROUND Recently, the safety of a new botulinum toxin (HU-014) was confirmed through animal experiments. The evaluation of the efficacy and safety of this newly introduced botulinum toxin is required considering the risk of adverse events (AEs) and need for standardization before its universal use. OBJECTIVE The aim of this multicenter, double-blind, randomized, parallel, active-controlled phase III clinical trial was to investigate the noninferiority of HU-014 versus existing onabotulinumtoxin A for the treatment of moderate to severe glabellar lines. METHODS In total, 267 subjects were randomized to either the test (HU-014) or control (onabotulinumtoxin A) group. At the baseline and at weeks 4, 8, 12, and 16, investigator's live assessment, independent photographic assessment, subjects' improvement assessment, subjects' satisfaction assessment, and safety assessment were performed. RESULTS At week 4, the response rate was 90.15% and 92.31% in the test and control groups, respectively, as per investigator's live assessment while frowning, without a significant difference. Both groups also showed no significant differences in response rates in the other assessments. In addition, no serious AEs were reported. CONCLUSION HU-014 was noninferior to existing onabotulinumtoxin A in the treatment of glabellar lines at a 1:1 dose ratio, and both products were well tolerated. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.title | Efficacy and Safety of a New Botulinum Toxin (HU-014) Versus Existing Onabotulinumtoxin A in Subjects With Moderate to Severe Glabellar Lines | - |
dc.type | Article | - |
dc.identifier.doi | 10.1097/DSS.0000000000002789 | - |
dc.identifier.bibliographicCitation | DERMATOLOGIC SURGERY, v.47, no.3, pp E91 - E96 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000635152500005 | - |
dc.identifier.scopusid | 2-s2.0-85113273862 | - |
dc.citation.endPage | E96 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | E91 | - |
dc.citation.title | DERMATOLOGIC SURGERY | - |
dc.citation.volume | 47 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.